Celldex Therapeutics (CLDX) Expected to Announce Earnings on Thursday

Key Points

• Celldex Therapeutics is set to announce its Q2 2025 earnings on August 14, with expectations of a loss of ($0.86) per share and revenue of $1.13 million.
• In the previous quarter, Celldex's earnings were ($0.81) per share, missing estimates, with a negative return on equity of 23.46%.
• Analysts hold a consensus rating of “Moderate Buy” on CLDX, with an average price target of $50.11, despite recent downgrades from firms like Goldman Sachs and UBS.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) will likely be releasing its Q2 2025 earnings data before the market opens on Thursday, August 14th. Analysts expect Celldex Therapeutics to post earnings of ($0.86) per share and revenue of $1.13 million for the quarter.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported ($0.85) earnings per share for the quarter, topping analysts' consensus estimates of ($0.86) by $0.01. The company had revenue of $0.73 million for the quarter, compared to analysts' expectations of $1.13 million. Celldex Therapeutics had a negative net margin of 2,366.07% and a negative return on equity of 23.46%. On average, analysts expect Celldex Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Celldex Therapeutics Stock Down 2.6%

NASDAQ:CLDX traded down $0.55 during mid-day trading on Friday, reaching $20.66. 770,909 shares of the stock were exchanged, compared to its average volume of 928,959. The company has a 50 day simple moving average of $21.54 and a 200-day simple moving average of $20.74. The stock has a market capitalization of $1.37 billion, a P/E ratio of -7.65 and a beta of 1.22. Celldex Therapeutics has a 1 year low of $14.40 and a 1 year high of $47.00.

Institutional Trading of Celldex Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Millennium Management LLC grew its position in shares of Celldex Therapeutics by 327.3% in the first quarter. Millennium Management LLC now owns 399,932 shares of the biopharmaceutical company's stock valued at $7,259,000 after purchasing an additional 306,330 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Celldex Therapeutics by 12.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 131,296 shares of the biopharmaceutical company's stock valued at $2,383,000 after buying an additional 14,979 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Celldex Therapeutics by 1.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company's stock worth $798,000 after acquiring an additional 680 shares during the period.

Wall Street Analysts Forecast Growth

CLDX has been the topic of several analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $50.00 price target on shares of Celldex Therapeutics in a research note on Friday, June 13th. UBS Group decreased their target price on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Morgan Stanley reduced their price target on Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating on the stock in a research report on Friday, May 9th. The Goldman Sachs Group reduced their target price on shares of Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th. Finally, Canaccord Genuity Group started coverage on shares of Celldex Therapeutics in a research note on Monday, April 28th. They set a "buy" rating and a $64.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $50.11.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.